— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share
— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected
— Net loss before recognition of the deemed dividends was $5.3 million
— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018
— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin
— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor
Most Popular
Key metrics from Shopify’s (SHOP) Q1 2024 earnings results
Shopify Inc. (NYSE: SHOP) reported first quarter 2024 earnings results today. Revenue increased 23% to $1.9 billion compared to the prior-year period. Gross Merchandise Volume (GMV) increased 23% year-over-year to
EA Earnings: Electronic Arts reports lower revenues for Q4 2024
Video game publisher Electronic Arts (NASDAQ: EA) Tuesday reported a decline in revenues for the fourth quarter of 2024. Meanwhile, the top line came in slightly above analysts' estimates. Fourth-quarter
What to look for when Home Depot (HD) reports Q1 2024 earnings
Shares of The Home Depot (NYSE: HD) stayed red on Tuesday. The stock has gained 17% over the past 12 months. The home improvement retailer is scheduled to report its
